Online Decision-Support Tool “TECHoice” for the Equipment Technology Choice in Sterile Filling Processes of Biopharmaceuticals

by Haruku Shirahata, Sara Badr, Yuki Shinno, Shuta Hagimori, Hirokazu Sugiyama
Published 2019-07-01

The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy

by Yuki Shinno, MD, Yasushi Goto, MD, PhD, Mayu Ohuchi, Akinobu Hamada, Hiroshi Nokihara, Yasuhiro Fujiwara, Yuichiro Ohe
Published 2020-03-01

Mixed response to osimertinib and the beneficial effects of additional local therapy

by Yuki Shinno, Yasushi Goto, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe
Published 2019-04-01

Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer

by Ryota Shibaki, Shuji Murakami, Yuki Shinno, Yuji Matsumoto, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noriko Motoi, Noboru Yamamoto, Yuichiro Ohe
Published 2019-04-01

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

by Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
Published 2021-09-01